CHRS Stock Price, Chart, Stats & News
Coherus Oncology, Inc. (CHRS) does not currently pay a dividend.
CHRS chart
Fundamentals
Gross margin | 67.24% |
Operating margin | -429.51% |
Pretax margin | -434.23% |
Net margin | 398.43% |
Effective tax rate | – |
ROA | 65.04% |
ROE | 789.35% |
D/E | 0.66x |
Interest coverage ratio | -20.12x |
CHRS valuation
P/E | – |
P/S | 4.53x |
P/B | 3.22x |
P/CF | -1.42x |
P/FCF | -1.38x |
P/OCF | -1.42x |
PEG | 0.15x |
EV multiple | -1.41x |
About
Coherus Oncology, Inc. is a biopharmaceutical company primarily focused on the research, development, and commercialization of cancer immunotherapies across the United States. The company's commercialized products include several biosimilar therapies. These comprise UDENYCA, a long-acting granulocyte-colony stimulating factor biosimilar to Neulasta; YUSIMRY, an equivalent to Humira, prescribed for inflammatory conditions like rheumatoid arthritis, psoriasis, and Crohn's disease, which are characterized by heightened tumor necrosis factor (TNF) production; and CIMERLI, a Lucentis biosimilar aimed at treating specific ophthalmic disorders such as neovascular age-related macular degeneration, macular edema, and diabetic retinopathy.
Similar securities
Based on sector and market capitalization
